Pharmaceuticals, Biotechnology and Life Sciences
Janssen Research & Development, LLC has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Invokamet extended release (XR).
Health Canada has accepted for review Janssen’s new drug submission (NDS) for daratumumab for treatment of Multiple Myeloma.
The OSIRIS trial Phase II a investigating once daily OLYSIO (simeprevir) in combination with sofosbuvir in hepatitis C virus (HCV) genotype 4 infected patients, with and without liver cirrhosis, demonstrated treatment to be safe.